Biomednewsbreaks - Volitionrx (NYSE American: VNRX) Nu.Q Nets H3.1 Study Reports Predictive Value In Sepsis

(MENAFN- Investor Brand Network) VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced the publication of a peer-reviewed paper reporting that its Nu.Q NETs H3.1 biomarker is an independent predictor of 28-day mortality and the need for renal replacement therapy in patients with sepsis and septic shock. Published in Critical Care Medicine, the study found significantly higher Nu.Q NETs H3.1 levels in septic shock patients than in sepsis patients and a dose-response relationship with acute kidney injury severity, supporting its potential use for risk stratification and early intervention. The journal also published an independent editorial examining H3.1 nucleosomes as a potential marker of NET-mediated organ injury.

Volition said the findings support ongoing commercial and licensing discussions for Nu.Q NETs, its nucleosome quantification technology designed to detect diseases associated with NETosis. The company believes the test could help clinicians anticipate disease progression, guide treatment decisions and monitor patients over time across acute and chronic conditions. Volition cited a total addressable market of $2.8 billion for the technology and said the latest findings add to previously published evidence supporting its potential clinical utility.

Dr Andrew Retter, Medical Consultant, Volition, said:

“Introducing Nu.Q NETs into hospitals, as a treatable, trackable trait, could lead to new ways of treating sepsis, improve patient survival and the quality of life of survivors.”

To view the full press release, visit:

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries: Louise Batchelor, Volition, [email protected], +44 (0)7557 774620

For further information, visit the company's website at

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio IBN: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

MENAFN27082026000224011066ID1111584189